-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
ZIKV-IN-2
| Category | Virus Protease |
| CAS | 910582-16-0 |
| Description | ZIKV-IN-2 (compound 3a) is a potent ZIKV NS5 methyl transferase (MTase) inhibitor with an IC50 value of 38.86 μM. ZIKV-IN-2 inhibits ZIKV replication and infection. ZIKV-IN-2 can be used in research of Zika virus (ZIKV). |
Product Information
| Molecular Weight | 574.75 |
| Molecular Formula | C39H42O4 |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| In Vitro | ZIKV-IN-2 (compound 3a; 0.08-50 μM) inhibits the expression of ZIKV E protein with an EC50 value of 6.17 μM and inhibits ZIKV replication and infection. ZIKV-IN-2 (0.08-50 μM; 96 h) has low cytotoxicity in Vero, Huh7 and A549 cells. Cell Viability Assay Cell Line: Vero, Huh7 and A549 cells Concentration: 0.08, 0.4, 2, 10, and 50 μM Incubation Time: 96 hours Result: Exhibited low cytotoxicities to Vero cells, Huh7 cells and A549 cells with CC50>200 μM to all three cell lines. |
| Target | IC50: 38.86 μM (MTase) |
